Details for Patent: 10,973,836
✉ Email this page to a colleague
Which drugs does patent 10,973,836 protect, and when does it expire?
Patent 10,973,836 protects FARXIGA and is included in one NDA.
Protection for FARXIGA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-seven patent family members in nineteen countries.
Summary for Patent: 10,973,836
| Title: | Methods of treating heart failure with reduced ejection fraction |
| Abstract: | The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life. |
| Inventor(s): | Anna Maria LANGKILDE |
| Assignee: | AstraZeneca AB |
| Application Number: | US16/812,745 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,973,836
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-002 | Jan 8, 2014 | AB | RX | Yes | Yes | 10,973,836*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,973,836
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 118963 | ⤷ Start Trial | |||
| Australia | 2020202887 | ⤷ Start Trial | |||
| Australia | 2021215150 | ⤷ Start Trial | |||
| Australia | 2023210548 | ⤷ Start Trial | |||
| Australia | 2025204486 | ⤷ Start Trial | |||
| Brazil | 112020008705 | ⤷ Start Trial | |||
| Canada | 3079175 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
